Ionis Pharmaceuticals Inc is a renowned biopharmaceutical company known for its commitment to scientific innovation and patient-centric solutions. The company's core values revolve around excellence, integrity, and collaboration. Ionis focuses on developing transformative RNA-targeted medicines to address a wide range of diseases with high unmet medical needs. With a strong corporate philosophy centered on rigorous scientific research, Ionis prioritizes the advancement of therapeutic solutions that improve patients' lives. Ionis Pharmaceuticals Inc's dedication to pioneering therapies and strategic partnerships underscores its mission to deliver novel treatments and drive positive healthcare outcomes.

Ionis Pharmaceuticals Inc is primarily present in the United States.

Ionis Pharmaceuticals Inc has achieved several significant milestones throughout its history. Notably, the company pioneered the development of antisense technology, a groundbreaking approach to target and modulate the production of disease-causing proteins. Ionis has successfully advanced multiple antisense therapies into clinical trials and gained regulatory approvals for several of its drugs. Additionally, the company has established numerous collaborations with leading biopharmaceutical companies, further validating its innovative drug discovery platform. Ionis Pharmaceuticals Inc continues to make strides in the field of RNA-targeted therapeutics, aiming to improve the lives of patients affected by various diseases.

Ionis Pharmaceuticals Inc, formerly known as Isis Pharmaceuticals Inc, is a renowned biotechnology company headquartered in Carlsbad, California. Established in 1989, Ionis specializes in discovering and developing RNA-targeted therapeutics for various diseases. The company's innovative antisense technology allows the targeting of specific genes to treat a wide range of medical conditions. Ionis is recognized for its industry-leading pipeline of drugs, focusing on areas such as cardiovascular, metabolic, and neurological disorders. With a strong commitment to advancing healthcare through groundbreaking research and development, Ionis Pharmaceuticals Inc has emerged as a prominent player in the biotech sector, consistently striving to improve patients' lives.

The main competitors of Ionis Pharmaceuticals Inc in the market are Alnylam Pharmaceuticals, Biogen, and Moderna.

Ionis Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Ionis Pharmaceuticals Inc. focuses on developing RNA-targeted drugs to treat various diseases. By harnessing the power of antisense technology, Ionis utilizes genetic information to create specific RNA-targeted therapies that can selectively modulate gene expression, preventing or treating diseases at the molecular level. Ionis collaborates with pharmaceutical partners worldwide to advance its drug candidates through clinical development and commercialization. With its extensive pipeline and groundbreaking platform, Ionis aims to revolutionize the treatment of genetic diseases and offer hope to patients in need.

مُعامل القيمة السوقية إلى الأرباح لـ Ionis Pharmaceuticals هو ؜-١٢٫٢٣.

مُعامِل القيمة إلى المبيعات Ionis Pharmaceuticals هو ١١٫٤١.

نقاط جودة AlleAktien لـ Ionis Pharmaceuticals هي 4/10.

المتوقعة Ionis Pharmaceuticals الإيرادات هي ٦٢٠٫٨٩ مليون. USD.

صافي الربح المتوقعة Ionis Pharmaceuticals هو ؜-٥٧٩٫١١ مليون. USD.

Ionis Pharmaceuticals Inc is a leading company in the field of RNA-based therapeutics. Since its founding in 1989, the company has been working to develop and bring to market innovative and effective therapies for numerous diseases. Today, the company employs over 800 people and is headquartered in Carlsbad, California. The business model of Ionis Pharmaceuticals is based on the development and commercialization of RNA-based therapeutics. These are drugs that are made based on ribonucleic acids (RNA). RNA is an important component of cells and is needed for the translation of genetic information into proteins. In the case of diseases, a disrupted RNA metabolism can lead to severe illnesses. Ionis Pharmaceuticals focuses on this aspect in the development of therapeutics and uses RNA to specifically intervene in disease mechanisms and correct them. The company has developed a broad portfolio of therapeutics. One of the most successful products is Spinraza, a medication for the treatment of spinal muscular atrophy (SMA), a hereditary disease of the motor nervous system. Spinraza is the first approved RNA-based therapeutic and has enabled a significant breakthrough in the development of this technology. Other products that the company has in its pipeline target the treatment of diseases such as diabetes, cancer, Alzheimer's, and other neurological disorders. The business model of Ionis Pharmaceuticals includes various divisions. In addition to the development of RNA-based therapeutics, the company also conducts research and development in the field of antisense technology. This involves the use of short nucleotide sequences to reduce protein expression. Unlike RNA therapy, antisense technology utilizes DNA. Ionis Pharmaceuticals is a pioneer in this field and has already developed numerous drugs based on this technology. Another important area for the company is the licensing and commercialization of therapeutics to partner companies. Ionis Pharmaceuticals has entered into a variety of collaborations with major pharmaceutical companies such as Roche, GlaxoSmithKline, and AstraZeneca. In these partnerships, the company is responsible for the development and clinical testing of the therapeutics, while the partners are responsible for the production, marketing, and distribution of the products. This allows Ionis Pharmaceuticals to leverage its expertise in RNA technology while benefiting from the distribution networks and experiences of its partner companies. Overall, the business model of Ionis Pharmaceuticals is positioned in a promising and rapidly growing market. The use of RNA and antisense technologies opens up completely new possibilities for the development of effective therapeutics for numerous diseases. With a broad portfolio of already approved and in-development drugs, as well as a strong partnership strategy, Ionis Pharmaceuticals is well-positioned to continue operating successfully in this field.

يوزع Ionis Pharmaceuticals أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Ionis Pharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـIonis Pharmaceuticals هو US4622221004.

رمز WKN لـ Ionis Pharmaceuticals هو A2ACMZ.

الرمز المُختصر لـ Ionis Pharmaceuticals هو IONS.

خلال آخر 12 شهراً، دفعت Ionis Pharmaceuticals توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Ionis Pharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Ionis Pharmaceuticals هي .

Ionis Pharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Ionis Pharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Ionis Pharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Ionis Pharmaceuticals المُعلن عنها في ١‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/٨‏/٢٠٢٤.

في العام 2023، وزعت Ionis Pharmaceuticals 0 USD كأرباح أسهم.

يتم توزيع أرباح Ionis Pharmaceuticals بالعملة USD.